-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Eli Lilly, Raises Price Target to $1316

Benzinga·10/21/2026 17:51:03
语音播报
Leerink Partners analyst David Risinger maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $1309 to $1316.